1. Home
  2. SKYE vs ACXP Comparison

SKYE vs ACXP Comparison

Compare SKYE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.18

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

N/A

Current Price

$0.95

Market Cap

5.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
ACXP
Founded
2012
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
5.8M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
SKYE
ACXP
Price
$1.18
$0.95
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
★ $68.00
$17.00
AVG Volume (30 Days)
★ 98.4K
86.5K
Earning Date
11-24-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.95
52 Week High
$11.68
$7.54

Technical Indicators

Market Signals
Indicator
SKYE
ACXP
Relative Strength Index (RSI) 44.62 32.44
Support Level $0.26 $0.95
Resistance Level $1.66 $1.77
Average True Range (ATR) 0.20 0.07
MACD -0.00 0.00
Stochastic Oscillator 62.05 12.81

Price Performance

Historical Comparison
SKYE
ACXP

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: